Junlong Wu1,2, Hongkai Wang1,2, Christopher J Ricketts3, Youfeng Yang3, Maria J Merino3, Hailiang Zhang1,2, Guohai Shi1,2, Hualei Gan2,4, W Marston Linehan3, Yao Zhu1,2, Dingwei Ye1,2. 1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. 3. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Abstract
BACKGROUND: An inherited susceptibility to renal cancers is associated with multiple predisposing genes, but most screening tests are limited to patients with a family history. Next-generation sequencing (NGS)-based multigene panels provide an efficient and adaptable tool for investigating pathogenic germline mutations on a larger scale. This study investigated the frequency of pathogenic germline mutations in renal cancer predisposition genes in patients with sporadic, early-onset disease. METHODS: An NGS-based panel of 23 known and potential renal cancer predisposition genes was used to analyze germline mutations in 190 unrelated Chinese patients under the age of 45 years who presented with renal tumors. The detected variants were filtered for pathogenicity, and then their frequencies were calculated and correlated with clinical features. Germline variants of the fumarate hydratase (FH) and BRCA1-associated protein 1 (BAP1) genes were comprehensively analyzed because of their aggressive potential. RESULTS: In total, 18 patients (9.5%) had germline mutations in 10 genes. Twelve of these 18 patients had alterations in renal cancer predisposition genes (6.3%), and 6 patients had mutations in potential predisposition genes such as BRCA1/2. Notably, pathogenic mutation carriers had a significant family history in second-degree relatives in comparison with those without pathogenic mutations (P < .001). Variants of unknown clinical significance in FH and BAP1 demonstrated evidence of additional somatic loss in tumors. CONCLUSIONS: In patients with early-onset disease, a multigene panel identified a high pathogenic germline mutation rate in renal cancer predisposition genes. This study emphasizes the importance of screening patients with early-onset disease for mutations in cancer predisposition genes. Germline screening should be encouraged in early-onset patients to provide personalized medicine and improve patient outcomes.
BACKGROUND: An inherited susceptibility to renal cancers is associated with multiple predisposing genes, but most screening tests are limited to patients with a family history. Next-generation sequencing (NGS)-based multigene panels provide an efficient and adaptable tool for investigating pathogenic germline mutations on a larger scale. This study investigated the frequency of pathogenic germline mutations in renal cancer predisposition genes in patients with sporadic, early-onset disease. METHODS: An NGS-based panel of 23 known and potential renal cancer predisposition genes was used to analyze germline mutations in 190 unrelated Chinese patients under the age of 45 years who presented with renal tumors. The detected variants were filtered for pathogenicity, and then their frequencies were calculated and correlated with clinical features. Germline variants of the fumarate hydratase (FH) and BRCA1-associated protein 1 (BAP1) genes were comprehensively analyzed because of their aggressive potential. RESULTS: In total, 18 patients (9.5%) had germline mutations in 10 genes. Twelve of these 18 patients had alterations in renal cancer predisposition genes (6.3%), and 6 patients had mutations in potential predisposition genes such as BRCA1/2. Notably, pathogenic mutation carriers had a significant family history in second-degree relatives in comparison with those without pathogenic mutations (P < .001). Variants of unknown clinical significance in FH and BAP1 demonstrated evidence of additional somatic loss in tumors. CONCLUSIONS: In patients with early-onset disease, a multigene panel identified a high pathogenic germline mutation rate in renal cancer predisposition genes. This study emphasizes the importance of screening patients with early-onset disease for mutations in cancer predisposition genes. Germline screening should be encouraged in early-onset patients to provide personalized medicine and improve patient outcomes.
Authors: Mohamed H Abdel-Rahman; Robert Pilarski; James B Massengill; Benjamin N Christopher; Ryan Noss; Frederick H Davidorf Journal: Melanoma Res Date: 2011-06 Impact factor: 3.599
Authors: Hong Truong; Sarah E Hegarty; Leonard G Gomella; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Veda N Giri Journal: J Genet Couns Date: 2017-01-19 Impact factor: 2.537
Authors: John J Bissler; J Christopher Kingswood; Elżbieta Radzikowska; Bernard A Zonnenberg; Michael Frost; Elena Belousova; Matthias Sauter; Norio Nonomura; Susanne Brakemeier; Petrus J de Vries; Vicky H Whittemore; David Chen; Tarek Sahmoud; Gaurav Shah; Jeremie Lincy; David Lebwohl; Klemens Budde Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Megan N Farley; Laura S Schmidt; W Marston Linehan; James Brugarolas; Jessica L Mester; Samuel Pena-Llopis; Andrea Pavia-Jimenez; Alana Christie; Cathy D Vocke; Christopher J Ricketts; James Peterson; Lindsay Middelton; Lisa Kinch; Nick Grishin; Maria J Merino; Adam R Metwalli; Chao Xing; Xian-Jin Xie; Patricia L M Dahia; Charis Eng Journal: Mol Cancer Res Date: 2013-05-24 Impact factor: 5.852
Authors: Hong Truong; Rania Sheikh; Ritesh Kotecha; Yelena Kemel; Peter A Reisz; Andrew T Lenis; Nikita N Mehta; Aliya Khurram; Vijai Joseph; Diana Mandelker; Alicia Latham; Ozge Ceyhan-Birsoy; Marc Ladanyi; Neil J Shah; Michael F Walsh; Martin H Voss; Chung-Han Lee; Paul Russo; Jonathan A Coleman; A Ari Hakimi; Darren R Feldman; Zsofia K Stadler; Mark E Robson; Robert J Motzer; Kenneth Offit; Sujata Patil; Maria I Carlo Journal: Eur Urol Oncol Date: 2021-10-12
Authors: Bryndis Yngvadottir; Avgi Andreou; Laia Bassaganyas; Alexey Larionov; Alex J Cornish; Daniel Chubb; Charlie N Saunders; Philip S Smith; Huairen Zhang; Yasemin Cole; Genomics England Research Consortium; James Larkin; Lisa Browning; Samra Turajlic; Kevin Litchfield; Richard S Houlston; Eamonn R Maher Journal: Hum Mol Genet Date: 2022-08-25 Impact factor: 5.121